So far, it is uncertain whether in vivo application of tribody [(HER2)2×Vγ9] or similar bispecific antibodies in the presence or absence of IDO inhibitors or other inhibitors can overcome an immunosuppressive tumor microenvironment by targeting tumor-infiltrating γδ T cells to tumor cells. The gene discussed is ERBB2; the disease is neoplasm.